Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.

Autor: Kaplonek P; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Wang C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Bartsch Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Gorman MJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Bowman K; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Kang J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Dayal D; Space Exploration Technologies Corporation, Hawthorne, CA, USA., Martin P; Space Exploration Technologies Corporation, Hawthorne, CA, USA., Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Villani AC; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Hsieh CL; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA., Charland NC; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., Gonye ALK; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Gushterova I; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Khanna HK; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., LaSalle TJ; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Lavin-Parsons KM; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., Lilley BM; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., Lodenstein CL; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., Manakongtreecheep K; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Margolin JD; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., McKaig BN; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., Rojas-Lopez M; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Microbiology, Harvard Medical School, Boston, MA, USA.; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Russo BC; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Microbiology, Harvard Medical School, Boston, MA, USA.; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Sharma N; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Tantivit J; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Thomas MF; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.; Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Sade-Feldman M; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Julg B; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Nilles EJ; Brigham and Women's Hospital, Boston, MA, USA., Musk ER; Space Exploration Technologies Corporation, Hawthorne, CA, USA., Menon AS; Space Exploration Technologies Corporation, Hawthorne, CA, USA., Fischer ES; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., McLellan JS; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA., Schmidt A; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA., Goldberg MB; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Microbiology, Harvard Medical School, Boston, MA, USA.; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA., Filbin MR; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA., Hacohen N; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Lauffenburger DA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA., Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
Jazyk: angličtina
Zdroj: Science immunology [Sci Immunol] 2021 Oct 15; Vol. 6 (64), pp. eabj2901. Date of Electronic Publication: 2021 Oct 15.
DOI: 10.1126/sciimmunol.abj2901
Abstrakt: The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2–specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across β-coronaviruses, we found that the early development of SARS-CoV-2–specific immunity occurred in tandem with preexisting common β-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
Databáze: MEDLINE